AdageneADAG
Market Cap: $93.9M
About: Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Employees: 174
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3% less capital invested
Capital invested by funds: $34.6M [Q1] → $33.7M (-$872K) [Q2]
2.3% less ownership
Funds ownership: 22.63% [Q1] → 20.33% (-2.3%) [Q2]
18% less funds holding
Funds holding: 17 [Q1] → 14 (-3) [Q2]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Arthur He 48% 1-year accuracy 14 / 29 met price target | 136%upside $5 | Buy Reiterated | 18 Sept 2024 |
HC Wainwright & Co. Arthur He 48% 1-year accuracy 14 / 29 met price target | 136%upside $5 | Buy Reiterated | 22 Jul 2024 |
HC Wainwright & Co. Arthur He 48% 1-year accuracy 14 / 29 met price target | 136%upside $5 | Buy Reiterated | 28 Jun 2024 |
Financial journalist opinion
Based on 3 articles about ADAG published over the past 30 days